[Federal Register Volume 86, Number 132 (Wednesday, July 14, 2021)]
[Notices]
[Page 37116]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-14958]



[[Page 37116]]

-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-21-2021]


Foreign-Trade Zone (FTZ) 99--Wilmington, Delaware; Authorization 
of Production Activity; AstraZeneca Pharmaceuticals LP (Pharmaceutical 
Products); Newark, Delaware

    On March 11, 2021, AstraZeneca Pharmaceuticals LP submitted a 
notification of proposed production activity to the FTZ Board for its 
facility within Subzone 99D, in Newark, Delaware.
    The notification was processed in accordance with the regulations 
of the FTZ Board (15 CFR part 400), including notice in the Federal 
Register inviting public comment (86 FR 14867-14868, March 19, 2021). 
On July 9, 2021, the applicant was notified of the FTZ Board's decision 
that no further review of the activity is warranted at this time. The 
production activity described in the notification was authorized, 
subject to the FTZ Act and the FTZ Board's regulations, including 
Section 400.14.

    Dated: July 9, 2021.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2021-14958 Filed 7-13-21; 8:45 am]
BILLING CODE 3510-DS-P